Cantor Fitzgerald Forecasts Lower Earnings for NeuroPace

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of NeuroPace in a research note issued to investors on Wednesday, January 29th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($0.80) per share for the year, down from their previous estimate of ($0.79). The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. The company had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same period in the previous year, the company posted ($0.28) earnings per share.

A number of other research firms have also recently commented on NPCE. UBS Group began coverage on NeuroPace in a research note on Tuesday, January 21st. They issued a "buy" rating and a $17.00 target price on the stock. JPMorgan Chase & Co. raised their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company increased their price target on shares of NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.80.

NeuroPace Stock Up 1.8 %

Shares of NPCE stock traded up $0.24 during trading hours on Friday, hitting $13.85. 123,881 shares of the company's stock traded hands, compared to its average volume of 163,820. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The stock's fifty day simple moving average is $11.89 and its two-hundred day simple moving average is $8.92. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.15. The stock has a market cap of $413.42 million, a price-to-earnings ratio of -13.85 and a beta of 2.05.

Institutional Investors Weigh In On NeuroPace

A number of large investors have recently added to or reduced their stakes in the stock. KCK LTD. purchased a new position in shares of NeuroPace in the 4th quarter worth $58,981,000. Millennium Management LLC boosted its position in NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company's stock worth $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of NeuroPace by 8.7% during the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company's stock valued at $2,211,000 after purchasing an additional 25,330 shares during the period. State Street Corp increased its position in shares of NeuroPace by 9.1% during the 3rd quarter. State Street Corp now owns 155,490 shares of the company's stock valued at $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of NeuroPace by 21.2% in the 4th quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company's stock worth $328,000 after purchasing an additional 5,133 shares during the period. Institutional investors own 78.83% of the company's stock.

Insider Buying and Selling at NeuroPace

In other news, insider Martha Morrell sold 3,200 shares of the business's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the completion of the transaction, the insider now directly owns 87,062 shares of the company's stock, valued at $1,306,800.62. The trade was a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 22.20% of the company's stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.